These data suggest that the ideal drug to improve survival in sepsis should reduce the over-reaction of the inflammatory response and, in parallel, should improve insulin signaling in the PI3K/Akt pathway, without inducing hypoglycemia. This evidence concerns the gene INS and Sepsis.